Scientists have developed a fully human antibody that halted the growth and spread of aggressive prostate cancer in preclinical research. Although more testing is needed, the drug’s unusual mechanism ...
On Wednesday, Defense Secretary Pete Hegseth made the startling announcement that the US military would begin requiring all ...
PDUFA target action date set to 18 December 2026LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted ...
WSW, NY, July 15th, 2026, FinanceWireOn July 6, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) agreed to acquire Crinetics ...
Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...
Prolactinomas are the most common functional pituitary neuroendocrine tumors, accounting for nearly half of all hormone-secreting pituitary adenomas. They can cause a wide range of symptoms, including ...
Prolactinomas are the most common functional pituitary neuroendocrine tumors, accounting for nearly half of all ...
Prolactinomas are the most common hormone-secreting pituitary tumors, but their diagnosis and management can be challenging ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
In a small cohort of patients with Cushing’s disease, most had their urinary free cortisol normalized after being ...
Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results